Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xueshuanxinmaining Tablet for Stable Angina Pectoris
NCT04270279Phase 4Unknown
- Sponsor
- Guang'anmen Hospital
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Botanical Extract
01
Overview
Phase 4, randomised, double-blind trial in stable angina pectoris comparing Xueshuanxinmaining Tablet with Placebo (2 arms). Primary endpoint: Stopping or reducing rate of antianginal drugs at 8 weeks. Status: unknown.
02
Drugs
xueshuan xinmaining
03
Conditions
stable angina pectoris
Beyond the preview
Go deeper on NCT04270279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270279.